BioLife Solutions (BLFS) AI Stock Analysis

• Market Cap: $1.02B
• Dividend Yield: N/A
• Average Volume (3M): 587.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.98
• Revenue Growth: -23.12%
• EPS Growth: 97.46%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 48
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.01
• Shares Outstanding: 47,561,172
• 10 Day Avg. Volume: 671,146
• 30 Day Avg. Volume: 587,139
• PEG Ratio: >-0.01
• Price to Book (P/B): -3.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -40.96
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 1.92
• Enterprise Value/Gross Profit: 13.13
• Enterprise Value/Ebitda: -11.40
• 1Y Price Target: $31.33
• Price Target Upside: 47.64% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 56 Neutral
• Price Target: $22.50 ▲(6.03%Upside)

BioLife Solutions' overall stock score reflects a combination of financial challenges and positive future prospects. The most significant factor is the strong performance and positive sentiment from the recent earnings call, which showcases revenue growth and improved profitability. However, financial performance issues, particularly profitability and valuation concerns, weigh down the score. Technical analysis suggests mixed signals, with some indicators pointing towards potential positive momentum.

Positive Factors

Acquisition

The acquisition of PanTHERA CryoSolutions is expected to enhance BioLife's capabilities in cryopreservation solutions.

Financial Performance

BioLife Solutions reported strong financial performance in 4Q24, with total revenue exceeding projections and a net loss lower than expected.

Product Development

BioLife's media is manufactured in the US, reducing exposure to tariffs and China-related risks.

Negative Factors

Growth Risks

Risks include lower-than-projected growth of products and services and potential fluctuation of sales in emerging markets.

Revenue Decline

Total revenue was $23.9M, representing 24.5% YoY decline and missing our projection of $26.0M.

BioLife Solutions Business Overview & Revenue Model

Company Description

BioLife Solutions, Inc. (BLFS) is a leading developer, manufacturer, and supplier of bioproduction tools and services for the cell and gene therapy and broader biopharma markets. The company's core products include proprietary biopreservation media, automated thawing devices, and cloud-connected cold chain management systems. These solutions are designed to improve the shelf life and efficacy of biologic materials, thereby enhancing the quality and efficiency of the bioproduction process.

How the Company Makes Money

BioLife Solutions generates revenue primarily through the sale of its biopreservation media products, which are used to extend the shelf life and viability of biologic materials. In addition to product sales, the company earns income from its automated thawing devices and cloud-based cold chain management systems, which offer logistical solutions to ensure the safe transport and storage of temperature-sensitive materials. Strategic partnerships and collaborations with biopharma companies further bolster its revenue streams by expanding its market reach and adoption of its technologies. The company's earnings are significantly influenced by the growth and demand within the cell and gene therapy sectors, as well as its ability to innovate and meet the evolving needs of its clients.

BioLife Solutions Financial Statement Overview

Summary

BioLife Solutions faces challenges with declining revenue and profitability, evident in the negative net income and EBIT margins. Despite this, the company maintains a strong equity position and low leverage, providing some financial stability. Cash flow improvements are a positive signal, suggesting potential for recovery in operational efficiency.

Income Statement

BioLife Solutions shows declining revenue with a negative net income, indicating profitability issues. The Gross Profit Margin remains strong at 76.5% TTM, but EBIT and EBITDA margins are negative due to high operational costs. The TTM revenue decreased by 3.45% compared to the previous period, highlighting a downward trend.

Balance Sheet

The balance sheet reflects a solid equity base with an Equity Ratio of 89.2% TTM, suggesting financial stability. However, the company has experienced significant losses, impacting Return on Equity, which remains negative. The Debt-to-Equity Ratio is low at 0.08 TTM, indicating low leverage risk.

Cash Flow

Cash flow analysis shows improvement with positive operating cash flow of $14.63M TTM. Free Cash Flow has grown by 116.8% over the previous period, a positive sign. The Operating Cash Flow to Net Income Ratio is negative due to losses, but overall cash generation is improving.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
79.42M	82.25M	143.27M	161.76M	119.16M	48.09M
	Gross Profit
60.76M	57.75M	46.75M	53.82M	37.75M	27.44M
	EBIT
-4.19M	-7.13M	-70.83M	-39.91M	-30.37M	-3.33M
	EBITDA
3.39M	1.53M	-45.24M	-23.19M	-17.78M	1.07M
	Net Income Common Stockholders
-10.41M	-20.18M	-66.43M	-139.81M	-8.38M	2.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
88.58M	104.58M	51.70M	64.06M	69.87M	90.46M
	Total Assets
395.14M	399.49M	412.71M	450.23M	552.60M	234.83M
	Total Debt
26.95M	30.17M	42.69M	43.71M	26.88M	11.15M
	Net Debt
-40.00M	-65.21M	7.28M	24.27M	-42.99M	-79.30M
	Total Liabilities
42.52M	50.58M	75.05M	86.04M	71.85M	29.58M
	Stockholders Equity
352.62M	348.91M	337.66M	-246.91M	480.75M	205.25M
Cash Flow		Free Cash Flow
11.29M	5.20M	-18.88M	-18.87M	-13.22M	1.88M
	Operating Cash Flow
14.63M	8.43M	-12.50M	-8.49M	-4.84M	6.51M
	Investing Cash Flow
31.34M	58.30M	17.84M	-58.12M	-12.64M	-23.73M
	Financing Cash Flow
-8.82M	-6.78M	10.59M	16.32M	-2.78M	101.22M

BioLife Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 21.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Negative. The current price of 21.22 is below the 20-day moving average (MA) of 22.28, below the 50-day MA of 22.72, and below the 200-day MA of 24.65, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 41.52 is Neutral, neither overbought nor oversold. The STOCH value of 7.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLFS.

BioLife Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AZTA	62 Neutral	$1.37B	―	-2.00%	―	-2.76%	48.51%
BLFS	56 Neutral	$1.02B	―	-3.29%	―	-23.12%	97.46%
STAA	54 Neutral	$834.52M	55.81	-19.14%	―	-14.44%	-557.38%
Sector *	53 Neutral	$5.24B	3.32	-44.36%	6.63%	16.78%	-0.12%
PLSE	44 Neutral	$1.01B	―	-77.86%	―	―	-1.00%
KMTS	34 Underperform	$796.16M	―		―	―	―

BioLife Solutions Corporate Events

BioLife Solutions Strengthens Board with Tony J. Hunt Appointment

BioLife Solutions has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors effective January 2, 2025. Mr. Hunt, recognized for his leadership in bioprocessing innovation, is expected to enhance BioLife’s strategic focus on the CGT market with his extensive industry experience, contributing to the company’s growth and innovation efforts. This appointment reflects BioLife’s commitment to strengthening its position in the bioprocessing sector and supporting its mission of delivering top-tier bioproduction workflows.